02616.HK
CStone Pharmaceuticals
HKSE · Healthcare · Biotechnology · CN
HKD 6.19
+0.16%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.0x
Market Cap
HKD 8.59B
MomentumView details →
1D Return
+0.16%
YTD Return
+17.46%
RSI (14)
61.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.0x
Market Cap
HKD 8.59B
RSI (14)
61.5
MomentumView details →
1D Return
+0.16%
YTD Return
+17.46%
Similar companies
Latest newsMore news →
CStone Pharmaceuticals reported interim results for the six months ended June 2026, with revenue of RMB 205 million, up 315% year-on-year, and a narrowed net loss of RMB 252 million.8d agoCStone Pharmaceuticals repurchased 4.597 million shares in the open market last month, all intended for cancellation.44d ago